(2-氧代氮杂环庚-1-基)乙酸乙酯 | 61516-76-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: (2-氧代氮杂环庚-1-基)乙酸乙酯
• 英文名称: hexahydro-2-oxo-1H-azepine-1-acetic acid ethyl ester
• 英文别名: Ethyl (2-oxoazepan-1-yl)acetate；ethyl 2-(2-oxoazepan-1-yl)acetate
• CAS: 61516-76-5
• 化学式: C₁₀H₁₇NO₃
• mdl: MFCD06360129
• 分子量: 199.25
• InChiKey: DUMIQCQZFWRSNQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2933790090

反应信息

• 作为反应物：
  描述：

  (2-氧代氮杂环庚-1-基)乙酸乙酯 在 氨 作用下， 以 甲醇 为溶剂， 反应 72.0h， 以93%的产率得到2-(2-Oxo-1-azepanyl)acetamide
  参考文献：
  名称：

  Pharmacological activity of analogs and cycloanalogs of pyracetam

  摘要：

  DOI：

  10.1007/bf00765967
• 作为产物：
  描述：

  己内酰胺 生成 (2-氧代氮杂环庚-1-基)乙酸乙酯
  参考文献：
  名称：

  VOJNOVA V. N.; NAUMOV YU. A.; MARKINA V. V.; DREMOVA V. P., XIMIYA I PRIMENENIE PESTITSIDOV, M.,(1987) 8-10

  摘要：

  DOI：

文献信息

• Heterocycles useful in the treatment of benign prostatic hyperplasia
  申请人：Ortho-McNeil Pharmaceutical, Inc.

  公开号：US06384035B1

  公开（公告）日：2002-05-07

  This invention relates a to a series of heterocyclic substituted piperazines of Formula I pharmaceutical compositions containing them and intermediates used in their manufacture. The compounds of the invention selectively inhibit binding to the &agr;-1a adrenergic receptor, a receptor which has been implicated in benign prostatic hyperplasia. As such the compounds are potentially useful in the treatment of this disease.

  这项发明涉及一系列异环取代哌嗪的化合物I的制药组合物，以及用于其制备的中间体。该发明的化合物选择性地抑制与α-1a肾上腺能受体的结合，该受体已被认为与良性前列腺增生有关。因此，这些化合物在治疗这种疾病方面具有潜在的用途。
• USE OF CAPROLACTAM DERIVATIVE AS SOLVENT IN COSMETIC COMPOSITIONS; COSMETIC COMPOSITIONS COMPRISING IT
  申请人：Muller Benoit

  公开号：US20120269746A1

  公开（公告）日：2012-10-25

  The present invention relates to the use of at least one caprolactam derivative of formula (I) below: in which: n=0 or 1; m=0 or 1; p=0 to 13; R 1 is a linear or branched alkyl radical comprising a number t of carbon atoms of from 1 to 20; subject to the following conditions: (i) when p=0, m=0, (ii) when p=1 and n=1, m=1, (iii) when p=1 and n=0, m=0 and R 1 denotes a C 2 -C 20 alkyl radical; with the proviso that the sum of p+t is between 3 and 20, in a composition comprising, in a cosmetically acceptable medium, at least one liquid fatty phase and at least one lipophilic active agent, and containing no dibenzoylmethane-type UV screening agent, as a solvent for said active agent in said liquid fatty phase and/or as an agent improving the solubility of said active agent in the solid fatty phase. The present invention also relates to a composition comprising, in a cosmetically acceptable medium, at least one liquid fatty phase, characterized in that it comprises at least one caprolactam derivative of formula (I) as defined above and in that it does not contain a dibenzoylmethane-type UV screening agent.

  本发明涉及使用以下式(I)的至少一种己内酰胺衍生物：其中：n=0或1；m=0或1；p=0到13；R1是包含1到20个碳原子的线性或支链烷基，满足以下条件：(i)当p=0，m=0时，(ii)当p=1且n=1，m=1时，(iii)当p=1且n=0，m=0且R1表示C2-C20烷基；但p+t的总和在3到20之间，在包含至少一种液态脂肪相和至少一种亲脂性活性剂的化妆品可接受介质中，作为所述活性剂在所述液态脂肪相中的溶剂和/或作为改善所述活性剂在固态脂肪相中的溶解度的剂量。本发明还涉及一种化妆品可接受介质中含有至少一种液态脂肪相的组成物，其特征在于它包含上述定义的至少一种式(I)的己内酰胺衍生物，且不含二苯甲酮型紫外线筛选剂。
• Thiophene substituted piperazines useful in the treatment of benign prostatic hyperplasia
  申请人：Ortho-McNeil Pharmaceutical, Inc.

  公开号：EP1273572A1

  公开（公告）日：2003-01-08

  This invention relates to a series of heterocyclic substituted piperazines of Formula (I), pharmaceutical compositions containing them and intermediates used in their manufacture. The compounds of the invention selectively inhibit binding to the α-la adrenergic receptor, a receptor which has been implicated in benign prostatic hyperplasia. As such the compounds are potentially useful in the treatment of this disease.

  本发明涉及一系列式（I）的杂环取代哌嗪类化合物、含有这些化合物的药物组合物以及用于制造这些化合物的中间体。本发明的化合物可选择性地抑制与 α-la 肾上腺素能受体的结合，该受体与良性前列腺增生症有关。因此，本发明化合物可用于治疗这种疾病。
• Novel heterocycles useful in the treatment of benign prostatic hyperplasia
  申请人：——

  公开号：US20020165219A1

  公开（公告）日：2002-11-07

  This invention relates a to a series of heterocyclic substituted piperazines of Formula I 1 pharmaceutical compositions containing them and intermediates used in their manufacture. The compounds of the invention selectively inhibit binding to the &agr;-1a adrenergic receptor, a receptor which has been implicated in benign prostatic hyperplasia. As such the compounds are potentially useful in the treatment of this disease.

  本发明涉及一系列式 I 的杂环取代的哌嗪类化合物 1 含有这些化合物的药物组合物以及用于制造这些化合物的中间体。本发明的化合物可选择性地抑制与&agr;-1a肾上腺素能受体的结合，该受体与良性前列腺增生症有关。因此，本发明化合物可用于治疗这种疾病。
• VOJNOVA V. N.; NAUMOV YU. A.; MARKINA V. V.; DREMOVA V. P., XIMIYA I PRIMENENIE PESTITSIDOV, M.,(1987) 8-10
  作者：VOJNOVA V. N.、 NAUMOV YU. A.、 MARKINA V. V.、 DREMOVA V. P.

  DOI：——

  日期：——